Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

· Issued by Veraxa Biotech AG

Summary by 6ix AI

An article published by IBN reviews VERAXA Biotech, a Swiss biotechnology company developing cancer therapies, and its pipeline centered on its proprietary BiTAC platform, alongside antibody-drug conjugate (an antibody linked to a cell-killing drug) and engineered-antibody technologies.

Key details

  • VERAXA began trading on the NASDAQ Capital Market under the ticker VRXA in June 2026 after completing its business combination with Voyager Acquisition Corp.
  • The transaction came with financing arrangements that included a $27.5 million senior secured note and a securities purchase agreement.
  • VERAXA says BiTAC is designed as an "AND-gated" approach, in which two complementary components must engage the same cancer cell before the intended cell-killing mechanism is activated.
  • VERAXA has reported early preclinical (laboratory, before human testing) evidence for its BiTAC-TCE and BiTAC-ADC approaches, including a lab-dish proof of concept for BiTAC-ADC announced in June.
  • VERAXA appointed Raju Willener as CFO and Christoph Erkel, Ph.D., as chief scientific officer.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/veraxa-biotech-nasdaq-vrxa-builds-oncology-pipeline-around-bitac-platform-public-market-story-enters-next-phase

Featured Image

Austin, Texas, United States, September 22nd, 2026, NewsDirect

  • VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies.
  • The company entered the NASDAQ market in June 2026 following its completed business combination with Voyager Acquisition Corp., giving VERAXA access to the U.S. public markets as it advances its development programs.
  • BiTAC is designed as an "AND-gated" therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated.
  • VERAXA has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in June.
  • Recent corporate developments include the appointment of Raju Willener as CFO and Christoph Erkel, Ph.D., as chief scientific officer, adding financial and antibody-development expertise.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is entering a new phase of development following its transition to the NASDAQ market and a series of scientific and corporate milestones that have expanded the company's focus around its proprietary BiTAC(R) platform.

The Swiss biotechnology company began trading on the NASDAQ Capital Market under the ticker VRXA in June following the completion of its business combination with Voyager Acquisition Corp. The transaction was accompanied by financing arrangements that included a $27.5 million senior secured note and a securities purchase agreement for up to...

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Corporate Communications

IBN Austin, Texas www.IBN.ai 512.354.7000 Office Editor@IBN.ai

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Story so far

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases